Other Events ·
Nasdaq notifies Cognition Therapeutics of $1.00 minimum bid price deficiency with 180 days to cure
CGTXCognition Therapeutics Inc
Cognition Therapeutics received a Nasdaq deficiency letter on November 3, 2026, notifying the company that its common stock has traded below the $1.00 per share minimum bid price requirement for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting proceedings and potential reverse stock splits. Concurrently, the company reported third-quarter financial results showing a net loss of $4.1 million, or $0.04 per share, with cash reserves of approximately $31.5 million as of September 30, 2026. Cognition Therapeutics is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative disorders.